Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

The Philadelphia chromosome in leukemogenesis.

Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, Liu Q.

Chin J Cancer. 2016 May 27;35:48. doi: 10.1186/s40880-016-0108-0. Review.

2.

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches.

Carotta S.

Front Immunol. 2016 Apr 21;7:152. doi: 10.3389/fimmu.2016.00152. eCollection 2016. Review.

3.

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.

Sochacki AL, Fischer MA, Savona MR.

Onco Targets Ther. 2016 Apr 15;9:2273-86. doi: 10.2147/OTT.S83868. eCollection 2016. Review.

4.

Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets.

Layton Tovar CF, Mendieta Zerón H.

Indian J Hematol Blood Transfus. 2016 Jun;32(2):141-53. doi: 10.1007/s12288-015-0609-z. Epub 2015 Oct 20. Review.

PMID:
27065575
5.

JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age.

Xu M, Tchkonia T, Ding H, Ogrodnik M, Lubbers ER, Pirtskhalava T, White TA, Johnson KO, Stout MB, Mezera V, Giorgadze N, Jensen MD, LeBrasseur NK, Kirkland JL.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6301-10. doi: 10.1073/pnas.1515386112. Epub 2015 Nov 2.

6.

NK Cell Proliferation Induced by IL-15 Transpresentation Is Negatively Regulated by Inhibitory Receptors.

Anton OM, Vielkind S, Peterson ME, Tagaya Y, Long EO.

J Immunol. 2015 Nov 15;195(10):4810-21. doi: 10.4049/jimmunol.1500414. Epub 2015 Oct 9.

PMID:
26453750
7.

Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.

Nata T, Basheer A, Cocchi F, van Besien R, Massoud R, Jacobson S, Azimi N, Tagaya Y.

J Biol Chem. 2015 Sep 11;290(37):22338-51. doi: 10.1074/jbc.M115.661074. Epub 2015 Jul 16.

PMID:
26183780
8.

Mouse ENU Mutagenesis to Understand Immunity to Infection: Methods, Selected Examples, and Perspectives.

Caignard G, Eva MM, van Bruggen R, Eveleigh R, Bourque G, Malo D, Gros P, Vidal SM.

Genes (Basel). 2014 Sep 29;5(4):887-925. doi: 10.3390/genes5040887. Review.

9.

Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100.

Lee CE, Fulcher DA, Whittle B, Chand R, Fewings N, Field M, Andrews D, Goodnow CC, Cook MC.

Blood. 2014 Nov 6;124(19):2964-72. doi: 10.1182/blood-2014-06-578542. Epub 2014 Sep 18.

10.

The molecular regulation of Janus kinase (JAK) activation.

Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN.

Biochem J. 2014 Aug 15;462(1):1-13. doi: 10.1042/BJ20140712. Review.

11.

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.

J Immunol. 2014 Jul 1;193(1):48-55. doi: 10.4049/jimmunol.1400063. Epub 2014 Jun 2.

12.

Human lymphoid development in the absence of common γ-chain receptor signaling.

Kohn LA, Seet CS, Scholes J, Codrea F, Chan R, Zaidi-Merchant S, Zhu Y, De Oliveira S, Kapoor N, Shah A, Abdel-Azim H, Kohn DB, Crooks GM.

J Immunol. 2014 Jun 1;192(11):5050-8. doi: 10.4049/jimmunol.1303496. Epub 2014 Apr 25.

13.

Molecular pathways: interleukin-15 signaling in health and in cancer.

Mishra A, Sullivan L, Caligiuri MA.

Clin Cancer Res. 2014 Apr 15;20(8):2044-50. doi: 10.1158/1078-0432.CCR-12-3603. Review.

14.

In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.

Takahashi Y, Byrareddy SN, Albrecht C, Brameier M, Walter L, Mayne AE, Dunbar P, Russo R, Little DM, Villinger T, Khowawisetsut L, Pattanapanyasat K, Villinger F, Ansari AA.

PLoS Pathog. 2014 Mar 6;10(3):e1003929. doi: 10.1371/journal.ppat.1003929. eCollection 2014 Mar.

15.

Fate of lymphocytes after withdrawal of tofacitinib treatment.

Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G, Tommasini A.

PLoS One. 2014 Jan 9;9(1):e85463. doi: 10.1371/journal.pone.0085463. eCollection 2014.

16.

Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.

Mezentsev AV, Bruskin SA, Soboleva AG, Sobolev VV, Piruzian ES.

Int J Biomed Sci. 2013 Sep;9(3):112-22.

17.

STATs and macrophage fusion.

Miyamoto T.

JAKSTAT. 2013 Jul 1;2(3):e24777. doi: 10.4161/jkst.24777. Epub 2013 Apr 23. Review.

18.

JAK-STAT and bone metabolism.

Li J.

JAKSTAT. 2013 Jul 1;2(3):e23930. doi: 10.4161/jkst.23930. Epub 2013 Aug 15. Review.

19.

Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.

Chen Y, Lan Q, Zheng T, Zhao N, Holford TR, Lerro C, Dai M, Huang H, Liang J, Ma S, Leaderer B, Boyle P, Chanock S, Rothman N, Zhang Y.

Leuk Res. 2013 Sep;37(9):1120-4. doi: 10.1016/j.leukres.2013.05.003. Epub 2013 Jun 12.

20.

Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice.

Oh YB, Ahn M, Lee SM, Koh HW, Lee SH, Kim SH, Park BH.

Exp Mol Med. 2013 May 17;45:e23. doi: 10.1038/emm.2013.43.

Items per page

Supplemental Content

Write to the Help Desk